Cargando…

A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

BACKGROUND: Treatment options are limited for participants with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that progressed after two or more prior therapies. Studies have shown that blockade of both lymphocyte-activation gene 3 (LAG-3) and programmed cell death protein 1 (PD-1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garralda, E., Sukari, A., Lakhani, N.J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., Palcza, J., Jha, S., Chaney, M., Abraham, A.K., Healy, J., Falchook, G.S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832734/ https://www.ncbi.nlm.nih.gov/pubmed/36493599 http://dx.doi.org/10.1016/j.esmoop.2022.100639

Ejemplares similares

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY
por: Gregory, G., et al.
Publicado: (2022)

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
por: Borchmann, Peter, et al.
Publicado: (2022)

T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
por: Timmerman, John, et al.
Publicado: (2022)

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
por: Herrera, A. F., et al.
Publicado: (2022)

P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Armand, Philippe, et al.
Publicado: (2023)

P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
por: Johnson, Nathalie, et al.
Publicado: (2023)

P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT
por: Timmerman, John, et al.
Publicado: (2023)

Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
por: Domingo-Musibay, Evidio, et al.
Publicado: (2018)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing
por: Anisetti, Bhrugun, et al.
Publicado: (2023)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
por: Senda, Masaya, et al.
Publicado: (2023)

Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery
por: Woods, Alexander D., et al.
Publicado: (2022)

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
por: O'Malley, David M., et al.
Publicado: (2022)

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
por: Le, Dung T., et al.
Publicado: (2020)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Successful pembrolizumab treatment of microsatellite instability‐high intrahepatic cholangiocarcinoma: A case report
por: Ikeda, Yuki, et al.
Publicado: (2021)

Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer
por: Kai, Yugo, et al.
Publicado: (2021)

The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer
por: Trullas, A., et al.
Publicado: (2021)

Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab
por: Naganuma, Atsushi, et al.
Publicado: (2020)

A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
por: Guedikian, Annie A., et al.
Publicado: (2021)

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
por: Atkinson, Victoria, et al.
Publicado: (2020)

Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High
por: Kawai, Koji, et al.
Publicado: (2021)

Endometrial Adenocarcinoma with Discordant Microsatellite Stability Status Treated with First-Line Pembrolizumab: A Case Report and Narrative Review
por: Grant, Christopher R., et al.
Publicado: (2023)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
por: Pfister, David G., et al.
Publicado: (2022)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Exposure-Lag-Response in Longitudinal Studies: Application of Distributed-Lag Nonlinear Models in an Occupational Cohort
por: Neophytou, Andreas M, et al.
Publicado: (2018)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
por: Zeng, Tian, et al.
Publicado: (2021)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Distributed lag non-linear models
por: Gasparrini, A, et al.
Publicado: (2010)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Taking the Lag out of Jet Lag through Model-Based Schedule Design
por: Dean, Dennis A., et al.
Publicado: (2009)

Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature
por: Helbig, M., et al.
Publicado: (2023)

Metastatic Malignant Perivascular Epithelioid Cell Tumors With Microsatellite Instability Within Lynch Syndrome Successfully Treated With Anti-PD1 Pembrolizumab
por: Djerroudi, Lounes, et al.
Publicado: (2023)

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
por: Barata, Pedro, et al.
Publicado: (2020)

Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report
por: Hidaka, Yoshifumi, et al.
Publicado: (2022)

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
por: Baretti, Marina, et al.
Publicado: (2023)

Lag Screw Trajectory in Supination-External Rotation Fractures: Does the Direction of the Fibula Lag Screw Have an Effect?
por: Singla, Amit, et al.
Publicado: (2021)

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer
por: Patel, Manish R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fsc9goivtfj21413ic8b668njb